China Biologic Products (CBPO) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
China Biologic Reports Financial Results for the Second Quarter of 2016
August 4, 2016 5:00 PM EDTBEIJING, Aug. 4, 2016 /PRNewswire/--Â China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2016.
Second Quarter 2016 Financial Highlights
Total sales in the second quarter of 2016 increased by 23.4% in RMB terms, or 15.5% in USD terms, to $91.4 million from $79.1 million in the same quarter of 2015. Gross profit increased by 15.2% to $59.9 million from $52.0 million in the same quarter of 2015. Gross margin decreased slightly to 65.6% from 65.8% in the... More


